Pediatric Migraine by Shah, Ubaid Hameed & Kalra, Veena
Hindawi Publishing Corporation
International Journal of Pediatrics
Volume 2009, Article ID 424192, 7 pages
doi:10.1155/2009/424192
Review Article
PediatricMigraine
UbaidHameedShahandVeenaKalra
Apollo Centre for Advanced Pediatrics, Indraprastha Apollo Hospital, New Delhi, India
Correspondence should be addressed to Veena Kalra, kalra.veena@gmail.com
Received 12 December 2008; Revised 5 March 2009; Accepted 16 March 2009
Recommended by George Jallo
Migraine is the most common cause of acute recurrent headaches in children. The pathophysiological concepts have evolved
from a purely vascular etiology to a neuroinﬂammatory process. Clinical evaluation is the mainstay of diagnosis and should also
includefamilyhistory.Investigationshelptoruleoutsecondarycauses.Theroleofnewdrugsintreatmentofmigraineisdiscussed
and trials are quoted from literature. Indications for starting prophylaxis should be evaluated based on frequency of attacks and
inﬂuence on quality of life. For management of acute attacks of migraine both acetaminophen and ibuprofen are recommended
for use in children. Many drugs like antiepileptic drugs (AED), calcium channel blockers, and antidepressants have been used for
prophylaxisofmigraineinchildren.Thedataforuseofnewerdrugsformigraineinchildrenislimited,thoughAEDsareemerging
a popular choice. Biofeedback and other nonmedicinal therapies are being used with promising results.
Copyright © 2009 U. H. Shah and V. Kalra. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Headache is a disabling neurological disorder of varied
etiologies and a frequent health problem in children and
adolescents [1]. Headaches in children can be a primary
disorder or secondary to a number of causes. The four
categories of primary headaches are: migraine, tension-
type headache (TTH), cluster headache and trigeminal
autonomic cephalalgias, and other primary headaches [2]
(Table 1). Secondary headaches include conditions related
to intracranial and extracranial infections, intracranial mass
lesions, and head and neck trauma. Chronic recurrent
headaches occur in approximately 40% of children at age
of seven, increasing to 75% by the age of ﬁfteen years. Pre-
pubertal boys are more aﬀected than girls, but after puberty,
headaches are more common in girls [3]. Migraine is the
most common cause and accounts for more than half the
casesofrecurrentheadachesinchildren[4].Withsuchahigh
prevalence in school-aged children, migraine has signiﬁcant
eﬀect on school attendance and family dynamics involved in
caring for a sick child, with loss of job productivity and work
attendance in parents [5].
2. DiagnosticCriteriaof PediatricMigraine
Pediatric migraine diﬀers from adult migraine in pre-
sentation and response to treatment. It tends to be of
shorter duration and is more often bilateral. Migraine is
divided into six major categories (Table 1), the two most
important of which are migraine without aura (Table 2)a n d
migraine with aura. Under the new classiﬁcation of 2004
[2], headaches of bilateral location and also those of shorter
duration (one hour instead of two hours) are currently
modiﬁed for migraine diagnosis in children. The criteria for
ophthalmoplegic “migraine” now have been placed under
“cranial neuralgias and central causes of facial pain,” and
criteria for chronic migraine have been added. If a patient
fulﬁls the criteria for more than one type of migraine, each
type should be diagnosed.
3.Pathophysiology ofMigraine
The pathophysiological concepts of migraine have advanced
considerably over the last 20 years. The much popular
vascular theory of migraine by Wolﬀ has been undermined
by phase model of migraine by Blau [6]a n dc e r e b r a l
Doppler ﬂow studies by Olesen et al. [7]w h od e m o n -
strated that vasoconstriction did occur, but the timing of
vasoconstriction did not precede the aura and continued
well into the headache phase of the migraine. Migraine is
now considered to originate in the brain, thus making it a
neurological rather than vascular disease. According to this
neurogenic theory the genetically sensitive migraine brain2 International Journal of Pediatrics
Table 1: International Classiﬁcation of Headache Disorders.
Migraine
Migraine without aura
Migraine with aura
Childhood periodic syndromes that are commonly precursors of
migraine
Retinal migraine
Complications of migraine
Probable migraine
Tension-type headache (TTH)
Infrequent episodic tension-type headache
Frequent episodic tension-type headache
Chronic tension-type headache
Probable tension-type headache
Cluster headache and other trigeminal autonomic cephalalgias
Cluster headache
Paroxysmal hemicrania
Short-lasting unilateral neuralgiform headache attacks with
conjunctival injection and tearing (SUNCT)
Probable trigeminal autonomic cephalalgia
Other primary headaches
Primary stabbing headache
Primary cough headache
Primary exertional headache
Primary headache associated with sexual activity
Hypnic headache
Primary thunderclap headache
Hemicrania continua
New daily-persistent headache (NDPH)
Table 2: Diagnostic criteria for Pediatric migraine without aura.
A ≥5 attacks fulﬁlling features B to D
B Headache attack lasting 1 to 72 hours
C Headache has at least 2 of the following 4 features:
(1) Bilateral or unilateral (frontal/temporal) location
(2) Pulsating quality
(3) Moderate to severe intensity
(4) Aggravated by routine physical activity
D At least one of the following accompanies headache:
(1) Nausea and/or vomiting
(2) Photophobia and phonophobia (may be inferred
from their behavior)
when exposed to a migraine-inducing environment under-
goes neurochemical alterations resulting in premonitory
symptoms. This alteration in neurochemical balance of the
central nervous system leads to trigeminovascular activation
with the release of vasoactive peptides and neurogenic
inﬂammation. This in turn lowers the sensory threshold
for trigeminal input entering the brainstem at the Nucleus
Claudalis of the Trigeminal Nerve. Sensory input from the
C1 and C2 dermatomes integrates with the trigeminal input,
and eventually synapses in the somatosensory and limbic
cortex, where it is interpreted into conscious awareness
as headache. The characteristic form and development of
sensory disturbances and demonstration of unique changes
of brain blood ﬂow during migraine auras suggest that
the underlying mechanism is the spreading depression in
cerebral cortex. The cortical spreading depression, which
may be a key to an understanding of the migraine attack,
is a short-lasting depolarization wave that moves across the
cortex at a rate of 3–5mm/min. A brief phase of excitation
heralds the reaction which is immediately followed by pro-
longed nerve cell depression synchronously with a dramatic
failure of brain ion homeostasis, eﬄux of excitatory amino
acids from nerve cells, and enhanced energy metabolism
[8].
Calcitonin gene-related peptide has been implicated in
pathogenesis of migraine. Activation of trigeminal nerves
releases CGRP and other peptides which release proinﬂam-
matory mediators. These mediators further increase CGRP
synthesis and release over hours to days in correspondence
with the 4- to 72-hour duration of a typical migraine
episode. The increased CGRP synthesis and release might be
mediated by activation of mitogen-activated protein kinase
pathways, which, in turn, can be modulated by endogenous
inﬂammatory substances such as TNF-alpha and aﬀected by
d r u g ss u c ha ss u m a t r i p t a n .
It is now widely accepted that children with migraine
have a genetic predisposition that is in some way activated by
an environmental or physiological stimulus like exposure to
drugs,diet,stress,puberty,andsoforth.Majorbreakthrough
was an identiﬁcation of gene locus for familial hemiplegic
migraine in the Cav2.1 subunit of the gene for the P/Q type,
voltagegatedcalciumchannelonchromosome19.Sincethen
manygenemutationshavebeenidentiﬁedincasesoffamilial
hemiplegic migraine.
4. Evaluationof a Child with Headache
A detailed medical history is crucial. Assessment entails
about characteristics of headache: location (unilateral or
bilateral region); character (pulsating, pressing); severity and
eﬀect on ability to carry out daily activities; frequency and
duration, including number of days missed from school;
triggers; aggravating and relieving factors. Children with
“acute headaches” should be questioned for possible trauma,
symptoms suggestive of meningitis like fever, phono-
photophobia, and stiﬀness of neck. In “chronic progressive
headache” inquire about history of projectile vomiting, focal
weakness, and systemic illness. History of coexisting medical
disorders, emotional and social factors like academic failure,
bullying, and so forth, symptoms of depression, family
history of migraine, especially maternal, previous medica-
tions and their response, excessive use of multiple drugs,
and history suggestive of drug-induced problems should
always be part of medical history of a child with recurrent
headaches.International Journal of Pediatrics 3
Table 3: Diﬀerentiating Migraine from Tension-type headache.
Characteristics Migraine Tension-type headache
Pain features of
acute attacks
Throbbing Boring or squashing
Mostly unilateral Usually bilateral
Worsening of pain with
head movement
No eﬀect of head
movement
Associated
features
Nausea or vomiting None
Photophobia and
phonophobia
Triggering
factors
Altered sleep patterns
(too little or too much)
Psychological stress
Skipping meals
Overexertion
Change in stress level
(too much or relaxation)
Excess aﬀerent stimuli
(such as bright lights)
Menstruation
A thorough general physical examination, blood pres-
sure measurement, palpation of the head in search for
sinus tenderness, nuchal rigidity, and visual examination
should be done. Head circumference must be measured,
even in older children, because progressive increases in
intracranial pressure slowly cause macrocrania. Examine for
neurocutaneous syndrome, particularly neuroﬁbromatosis
and tuberous sclerosis, which are highly associated with
intracranial neoplasms. A detailed neurologic examination is
essential to look for any objective evidence of organic causes
of recurrent headaches. Fundus should be examined in
chronic headache and suspected raised intracranial pressure.
5.FeaturesSuggestingMigraineAs Causeof
Recurrent Headache in A Child
These include a positive family history, presence of trigger
factors, relief by sleep, impairment of the child’s social
functioning, and presence of aura symptoms. Migraine
in children is strongly associated with other childhood
periodic syndromes, for example, cyclical vomiting, abdom-
inal migraine, and benign paroxysmal vertigo. Very often,
children with migraine frequently suﬀer from travel sick-
ness and giddiness. Other strong associations are stress,
depression, and psychiatric comorbidities. Migraine needs
to be diﬀerentiated from Tension-type headache. Salient
diﬀerentiating features are highlighted in Table 3.
6. Role of Investigations
In childhood recurrent headaches without neurological
ﬁndings, current literature does not support performing
routine laboratory studies, lumbar puncture, or EEG as
part of the diagnostic evaluation. Investigate if history and
examination points toward a secondary cause of headache.
In2002AmericanAcademyofNeurologypublishedpractical
Table 4: Indications for neuroimaging in children with headache.
Acute headache
Chronic-progressive pattern
Focal neurologic symptoms
Abnormal neurologic examination
Presence of neurocutaneous syndrome
Changing pattern of headache
Age younger than three years
guidelines for role of diﬀerent investigations in children
withrecurrentheadachesunassociatedwithtrauma,fever,or
other provocative causes [9].
7. Neuroimaging
Neuroimaging is not routinely necessary in recurrent
headaches and a normal neurologic examination. Neu-
roimaging should be considered in children with an abnor-
mal neurologic examination, coexistence of seizures, or both
a n di fh i s t o r ys u g g e s t sr e c e n to n s e to fs e v e r eh e a d a c h e ,
increasing frequency of headache, change in the type of
headache, or subtle neurologic dysfunction (Table 4).
8.EEG
EEG is not recommended in the routine evaluation of a
child with recurrent headaches, as it is unlikely to provide an
etiology, improve diagnostic yield, or distinguish migraine
from other types of headaches. Pooled data indicates that the
EEGiseithernormalordemonstratesnonspeciﬁcabnormal-
ities in most headache patients. Nonspeciﬁc abnormalities
and benign epileptiform discharges are present in up to
10 percent of children with migraine, regardless of the
diagnosis [10]. Current data does not suggest diﬀerences in
EEG between children with migraine and nonmigraine type
headaches which may be diagnostically helpful. Hemiplegic
migraine has shown the most deﬁnite abnormal EEGs with
a wide variety of patterns. During the ictus, severe unilateral
or focal disturbances delta activity, theta-delta activity, theta
activity or alpha-reduction are described. In most cases EEG
changes subside in a few days and return to normal [11, 12].
9.LumbarPuncture
Lumbar puncture should be done when a child with acute
headache reveals signs of meningeal irritation or if there is
high suspicion of meningitis on clinical grounds.
10. Treatment of Migraine
Treatment of pediatric migraine includes an individually
tailoredregimenforacuteattackandprophylaxisofmigraine
using both nonpharmacologic and pharmacologic measures.
The successful treatment involves explaining the disease
process and reassuring the family.4 International Journal of Pediatrics
Table 5: Treatment of acute attacks of migraine.
Class Drug Comments
Analgesics
Ibuprofen, PO
7.5–10mg/kg
First line drug; safe and
eﬀective in children
Acetaminofen, PO
15mg/kg
Comparable eﬃcacy and
safety proﬁle with
ibuprofen
Nimuselide, PO
2.5mg/kg
Triptans
Sumatriptan Nasal
spray, 5mg, 20mg
Easy administration, faster
initial relief, and more side
eﬀects as compared to
placebo
Subcutaneous,
0.06mg/kg
Administration diﬃculty,
chest and neck discomfort,
and reported side eﬀects
Oral, 50 to 100mg Not eﬀective
Rizatriptan, PO, 5mg
Studied in adolescent;
adverse eﬀects reported
were fatigue, dizziness,
somnolence, dry mouth,
and nausea
Zolmitriptan, PO
2.5–5mg Evaluated in 12–17 years
Other
medication
Ketorolac IV
0.5mg/kg; maximum
30mg
IV prochlorperazine is
superior to IV ketorolac in
the acute treatment of
migraine headaches in
emergency department
prochlorperazine IV
(0.15mg/kg;
maximum 10mg)
11. Treatment of Acute Attacks of Migraine
(Table 5)
11.1. Analgesics. Acetaminophen and Ibuprofen are safe,
eﬀective and widely used for treatment of acute attacks
of migraine in children. The current evidence in litera-
ture shows that both are safe and eﬀective in aborting
the acute attack of migraine in children. Comparison of
eﬃcacy and safety at doses of 15mg/kg acetaminophen
and 10mg/kg ibuprofen, respectively, found no signiﬁcant
diﬀerences [13]. Similarly there is no diﬀerence in eﬃcacy,
safety and tolerability between acetaminophen 15mg/kg and
Nimuselide 2.5mg/kg [14]. Aspirin-containing compounds
are of concern in children younger than 15 years because
of the risk of Reye’s syndrome. Although a combination
of aspirin, caﬀeine, and acetaminophen is eﬀective in adult
acute migraine, it has not been tested in children for mild to
moderate migraines.
11.2. Triptans. The triptans, selective serotonin 5-HT1B/1D
agonists, are very eﬀective acute migraine drugs. They are
widely used in treatment of migraine attacks in adults and
are very eﬀective. However, children diﬀer in respose to
oral formulations of triptans as compared to adults. Oral
treatment has been assessed with sumatriptan, rizatriptan,
and zolmitriptan and found to be without beneﬁt [15–18].
In one trial of 32 patients zolmitriptan was superior to
placebo [19]. There is inadequate data for eﬀectiveness of
subcutaneous sumatriptan in children. In adolescents, only
intranasaladministrationhasdemonstratedeﬃcacy,forboth
sumatriptan and zolmitriptan [20–22].
12. Other Medications for Acute
MigraineAttacks
Other class of drugs used widely for treatment of migraine
attacks is ergot groups but current evidence ﬁnds no diﬀer-
ence in eﬀect between oral dihydroergotamine and placebo
[23]. Prochlorperazine is more eﬀective than ketorolac in the
reduction of symptoms 1 hour after intake in controlling
severe acute migrane attack in emergency department [24].
13. Prevention of Migraine Attacks
The indications for use of migraine prophylaxis in children
include missing more than 3 days of school for a month
or having 1 to 2 headaches for a week that interfere
with performing daily activities. Unresponsiveness to symp-
tomatic treatment, failure of non-pharmacological measures
to improve headache frequency, and/or presence of basilar
or hemiplegic migraine are also appropriate indications for
preventive therapy [25]. Many drugs have been used for
prevention of migrainous attacks in children, but there
is paucity of evidence to support their use in general.
Commonlyuseddrugsforpreventionofmigraineattacksare
tabulated in Table 6.
14.Beta Blockers andCalcium
ChannelBlockers
Beta-blockers are one of the most commonly prescribed
drugs for the prevention of migraine. Some controlled trials
have shown good results in adult [26]. Initial pediatric
trials showed inconsistent results with mixed success. Recent
Cochrane data base review found propranolol to be eﬀective
for prophylaxis of pediatric migraine [27]. The side eﬀects of
propranolol including insomnia, weight gain, tiredness, and
depressive symptoms often limit their role as prophylactic
agents in children.
Amongthecalciumchannelblockersonlyﬂunarizinehas
shown consistent eﬃcacy and safety as prophylactic agent for
paediatric migraine [27]. American academy of neurology’s
recommendations concluded that Flunarizine is probably
eﬀective for prophylaxis though it is not available in the
United States.
15. Anticonvulsant Therapy
There is growing interest in the use of anticonvulsant drugs
in prophylaxis of migraine. In children, small group studies
have shown eﬃcacy. Caruso et al. [28] reported that 31
children aged 7 to 16 years were responsive to Valproic acidInternational Journal of Pediatrics 5
Table 6: Drugs used for prevention of migraine attacks.
Class Drug & dosage Comments
Beta blockers Propranolol
3mg/kg/day
Reduced energy, tiredness, postural symptoms,
contraindicated in asthma, depressive side eﬀects, often
limits their usefulness in children
Calcium chanel blockers Flunarizine, PO, 5mg Not available in US
Nimodipine Not recommended for use in pediatric migraine
Anticonvulsants
Valproate
15–45mg/kg/day, PO
Drowsiness, weight gain, tremor, hair loss, fetal
abnormalities,haemato-logical or liver abnormalities
Topiramate
2–3mg/kg/day, PO
Found to be eﬀective in pediatric migraine. Side eﬀects
include cognitive changes, weight loss, and sensory
symptoms
Levetiracetam
250–500mg
Evaluated in pediatric migraine and found to be
eﬀective. About 10% children report somnolence,
dizziness, and irritability
Antidepressents
Amitriptyline
1mg/kg/day ,PO
Reduces headache frequency and severity; sedation
major side eﬀect
Trazodone
1mg/kg/day ,divided
TID, PO
Current literature: no evidence of beniﬁt
Pizotefen Current literature: no evidence of beniﬁt
in the 15–45-mg/kg dosage range, with 76% of patients
having a greater than 50% reduction in headache frequency,
while 18% had a greater than 75% reduction, and 6%
were headache-free. A study using standardized doses of
either 500mg or 1000mg of sodium divalproate in 9- to
17-year-old children also reported reduction in severity on
the 10 point Visual Analog Scale from 6.8 to 0.7, with a
decrease in headache frequency from 6 per month to 0.7
per month [29]. Winner et al. [30]r e p o r t e de ﬀectiveness
of topiramate in children and adolescents in dose of 2-
3mg/kg/day (maximum dose 200mg) with reduced mean
monthly migraine frequency from 5.4 days per month to
1.9 days per month. One retrospective study assessed the
eﬃcacy and safety of levetiracetam for pediatric migraine at
doses of 125–250mg twice daily and found that the mean
frequency of headache attacks fell from 6.3 to 1.7/month and
52% of patients experienced elimination of migraine attacks
during treatment. No side eﬀects were reported in 82.4%
but 10.5% discontinued treatment because of side eﬀects
including somnolence, dizziness, and irritability.
Cochrane review concluded that anticonvulsants appear
to be both eﬀective in reducing migraine frequency and
reasonably well tolerated. There was noticeable variation
among individual agents, but there are insuﬃcient data
to know whether this is due to chance or variation in
true eﬃcacy. Other anticonvulsant drugs like acetazolamide,
clonazepam, lamotrigine, and vigabatrin do not produce
results superior to placebo [31].
16. Other Medications for
ProphylaxisofMigraine
Cyproheptadine, an antihistamine with serotonine blocking
properties, has been used for migraine prophylaxis in
children in doses of 2 to 4mg/day showing reduction in
headache parameters with only few side eﬀects like weight
gain and sedation. Amitriptyline, at a dose of 1mg/kg per
day, has also shown eﬀectiveness in open-label trials. But
further trials are needed to recommend these drugs for
routine use in children [32].
17. Nonpharmacological or
Behavioral Therapy
The importance of nonmedicinal treatment deserves review.
The treatment methods include categories like promoting
adherence, education of the patient as well as maintaining
healthy lifestyle habits. These healthy lifestyle habits include
maintenance of adequate ﬂuid hydration, regular exercise
programs, not skipping meals, eating a balanced healthy
diet, and maintaining adequate sleep. Abstract reports have
demonstrated that skipping meals and sleep alterations
contribute to frequent headaches in adults and children,
and maintenance of healthy lifestyle habits may help overall
improve the outcome of childhood headache disorders.
Biobehavioralguidelinesareunderdevelopment,andfurther
study of the eﬀectivenss of biobehavioral management is
needed [33].
18. Biofeedback
Biofeedback is a technique intended to teach patients self-
regulation of certain physiologic processes not normally
considered to be under voluntary control. The technique
involves the feedback of a variety of types of information
notnormallyavailabletothepatient,followedbyaconcerted
eﬀort on the part of the patient to use this feedback to help
alter the physiological process in some speciﬁc way. The type6 International Journal of Pediatrics
of feedback used in an intervention depends on the nature
of the disease or disorder under treatment. For migraine
headaches, EMG measuring contraction of the frontalis
muscleandskintemperaturefeedbackdataareused(thermal
biofeedback). Thermal biofeedback is an eﬀective technique
used by many migraine patients to reduce the pain intensity
and frequency of their headaches. This is especially true of
pediatric migraineurs, particularly those who have entered
puberty. Patients achieve control through a combination
of visualization, voluntary relaxation, and mechanical feed-
back. In this technique, a temperature sensor is placed on the
ﬁnger, and the subject is taught to increase the temperature,
an eﬀect that is mediated through peripheral vasodilation.
Biofeedback training is done either in individual or group
sessions,aloneorincombination withotherbehavioralther-
apiesdesignedtoteachrelaxation.Atypicalprogramconsists
of 10 to 20 training sessions of 30 minutes each. Training
sessions are performed in a quiet, nonarousing environment.
Subjects are instructed to use mental techniques to aﬀect
the physiologic variable monitored. Typically, some type of
reward system is incorporated for successful alteration of
the feedback parameter. This reward may be in the form of
sensory signals such as lights or tone, verbal praise, or other
pleasant stimuli. At-home thermal biofeedback practice is
frequently more successful in children because they tend to
be more imaginative than adults. Relaxation training and
biofeedback have proven to be promising treatments for
children with migraine headaches. Feedback training was
accompanied by signiﬁcant reduction of cortical excitability.
This was probably responsible for the clinical eﬃcacy of
the training; a signiﬁcant reduction of days with migraine
and other headache parameters was observed. It is suggested
that normalization of the threshold regulation of cortical
excitability during feedback training may result in clinical
improvement [34].
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